Abstract
The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Current Respiratory Medicine Reviews
Title:When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis
Volume: 9 Issue: 3
Author(s): Mili E. Torok
Affiliation:
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Abstract: The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Export Options
About this article
Cite this article as:
Torok E. Mili, When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990016
DOI https://dx.doi.org/10.2174/1573398X113099990016 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Characterization and antiherpetic activity of native and chemically sulfated polysaccharide from <i>Adenanthera pavonina</i>
Current Pharmaceutical Biotechnology Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Approaches for Drug Delivery to Central Nervous System
Current Drug Delivery Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Methodologies to Assess Brain Drug Delivery in Lead Optimization
Current Topics in Medicinal Chemistry Preface
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Separating Fact from Fiction: The Data Behind Allergies and Side Effects Caused by Penicillins, Cephalosporins, and Carbapenem Antibiotics
Current Pharmaceutical Design Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Overview of Modern Surgical Management of Central Nervous System Tumors: North American Experience
Current Cancer Therapy Reviews Sepsis and Solid Organ Transplantation
Current Drug Targets The Coexistence of Olfactory Groove with Optic Nerve Sheath Meningioma Presenting with Anosmia: A Case Report
Current Medical Imaging Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) The Seattle Structural Genomics Center for Infectious Disease (SSGCID)
Infectious Disorders - Drug Targets Identification of Antifungal Agents Using Combinatorial Approach: An Overview$
Current Medicinal Chemistry - Anti-Infective Agents